**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 7009**

**Columns: REVIEW**

Optimizing diagnostic yield of EUS-FNA in pancreatic masses by rapid on-site evaluation

Iglesias Garcia J *et al*. EUS-FNA with ROSE in pancreatic masses

Julio Iglesias-Garcia, Jose Lariño-Noia, Ihab Abdulkader, J Enrique Domínguez-Muñoz

**Julio Iglesias-Garcia, Jose Lariño-Noia, J Enrique Domínguez-Muñoz,** Department of Gastroenterology and Hepatology, Foundation for Research in Digestive Diseases, University Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain

**Ihab Abdulkader,** Department of Pathology, University Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain

**Author contributions:** Iglesias-Garcia J substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data, drafting the article or revising it critically for important intellectual content; Lariño-Noia J and Abdulkader I, drafting the article or revising it critically for important intellectual content; Domínguez-Muñoz JE final approval of the version to be published.

**Correspondence to: Julio Iglesias-Garcia, MD, PhD,** Department of Gastroenterology and Hepatology, Foundation for Research in Digestive Diseases, University Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain. julio.iglesias.garcia@sergas.es

**Telephone:** +34-981-951364 **Fax:** +34-981-955100

**Received:** October 31, 2013  **Revised:** April 24, 2014

**Accepted:** May 19, 2014

**Published online:**

**Abstract**

Endoscopic ultrasound (EUS) has become an essential tool for the study of pancreatic diseases. Specifically, EUS plays a pivotal role evaluating patients with a known or suspected pancreatic mass. In this setting, differential diagnosis remains a clinical challenge. EUS–guided fine needle aspiration (FNA) and fine needle biopsy (FNB) has been proven to be a safe and useful tool in this setting. In fact EUS-guided FNA and FNB, by obtaining cytological and/or histological samples, are able to diagnose pancreatic lesions with a high sensitivity and specificity. In this context several methodological points, trying to increase the diagnostic yield of EUS-guided FNA and FNB, have been evaluated. In this review we will focus on the role of rapid on-site evaluation (ROSE). From data reported in the literature, ROSE may increase diagnostic yield of EUS-FNA specimens by 10%-30% and, thus, the diagnostic accuracy. However, we should point out that many recent studies reported adequacy rates of >90% without ROSE, indicating that, maybe, at high volume centers ROSE may not be indispensable to achieve excellent results. The use of ROSE can be considered important during the learning curve of EUS-FNA, and also in hospital with diagnostic accuracy rates lower than 90%.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Endoscopic ultrasound-guided fine needle aspiration; Rapid on-site evaluation; Solid pancreatic tumors; Accuracy

**Core tip:** Endoscopic ultrasound (EUS) has become a crucial tool for the evaluation of solid pancreatic masses. EUS–guided fine needle aspiration (FNA) and fine needle biopsy (FNB) has been proven to be a safe and useful tool in this setting, being able to diagnose pancreatic lesions with a high sensitivity and specificity. The use of rapid on-site evaluation can increase adequacy rates and diagnostic yield of EUS-guided FNA or FNB by 10%-30%

Iglesias-Garcia J, Lariño-Noia J, Abdulkader I, Domínguez-Muñoz JE. Optimizing the yield of EUS-guided fine needle biopsy in solid pancreatic masses. The role of rapid on-site evaluation. *World J Gastroenterol* 2014;In press

**INTRODUCTION**

Endoscopic ultrasound (EUS) has become a crucial tool in the study of pancreatic diseases. Specifically, EUS plays a pivotal role when evaluating patients with pancreatic solid tumors[1, 2]. In fact, distinguishing different types of pancreatic solid tumors is an important clinical challenge. Even more, therapeutic strategy in this context is based on the ability to determine the presence of a malignant lesion. Although ductal adenocarcinoma is considered as the main cause of pancreatic mass, many other neoplasms (*e.g.,* lymphoma, cystic tumors, and metastasis) and benign conditions (*e.g.,* chronic pancreatitis) with different prognoses and treatment options can be detected in the pancreas. Taking this into account, a cyto-pathological confirmation is highly relevant for establishing the best treatment.

EUS–guided fine needle aspiration (FNA) and fine needle biopsy (FNB) are considered safe and accurate methods for tissue sampling of intramural and extramural gastrointestinal lesions, including the pancreas. In fact EUS-guided FNA and FNB, by obtaining cytological and/or histological samples, are able to diagnose pancreatic lesions with a high sensitivity and specificity[3]. Several studies have evaluated the accuracy of cytology and/or histology after EUS-guided FNA or fine needle biopsy (FNB) for the diagnostic evaluation of pancreatic masses.

There are several methodological points, trying to increase the diagnostic yield of EUS-guided FNA and FNB being one of them the rapid on-site evaluation (ROSE). Although experts recommend an on-site evaluation of samples obtained in order to optimize the diagnostic yield of EUS-guided FNA, its effect on diagnostic accuracy has not been properly defined. In fact, reports on the need of ROSE during the procedure are scarce. In this review we will first analyze the role of EUS-guided FNA and FNB for the diagnosis of solid pancreatic masses. Finally we will present the most relevant data published analyzing the role of EUS-guided FNA and FNB with ROSE in this setting.

**USEFULNESS OF EUS-GUIDED FNA AND FNB IN THE DIFFERENTIAL DIAGNOSIS OF SOLID PANCREATIC TUMORS**

The role of EUS-guided FNA in the diagnosis of solid pancreatic tumors has been evaluated in many well-designed studies. Reported sensitivity and accuracy for malignancy ranges from 75% to 92% and from 79% to 92%, respectively[4-14]. Two large reviews have been published evaluating the accuracy of EUS-guided FNA in pancreatic masses. One of them included 28 studies (4225 patients). Authors evaluated the usefulness of EUS-FNA to differentiate between benign and malignant lesions. Sensitivity, specificity and diagnostic accuracy were 83% (54%–95%), 100% (71%–100%) and 88% (65%–96%), respectively[15]. The second one, a very recent meta-analysis, published by Hewitt *et al*[16], included 33 studies, including 4984 patients. Authors showed sensitivity for malignant cytology of 85% (95%CI: 84-86), and a specificity of 98% (95%CI: 97-99). When including atypical and suspicious cytology as true positive, sensitivity increased to to 91% (95%CI: 90-92); however, the specificity decreased to 94% (95%CI: 93-96). EUS-guided FNA also showed a very good positive predictive value (99%) and a good negative predictive value (64%). However, it is important to point out that in cases with findings related to chronic pancreatitis, the sensitivity of EUS-guided FNA for the detection of malignancy is clearly decreased[17, 18].

In order to optimize tissue retrieval, with the aim of obtaining core specimens, various EUS-guided techniques have been explored. One approach is the use of the tru-cut needle (Quick-Core®), with variable success and complication rates[19-21]. This tru-cut needle has demonstrated that histological samples can be obtained quite safely[21, 22]. However, there are certain limitations with the Quick-Core® needle that preclude its use in clinical routine. Most importantly, its diagnostic yield is strongly limited for lesions located at pancreatic head, related to the mechanical friction of the needle firing mechanism associated with the bended position of the scope[23-25]. In this setting a novel needle has been designed (ProcoreTM histology needle) to overcome tru-cut needle limitations (mainly in the second portion of the duodenum). A first study published with the 19-gauge caliber needle allowed a histological evaluation with an overall accuracy of 85.9% (89.4% in pancreatic solid lesions)[26], with a very high inter-observer agreement between pathologist when evaluating the quality of the samples obtained[27]. A new study has been recently published using the 22-gauge ProcoreTM needle in pancreatic masses, being able to obtain a sample suitable for histological evaluation in 88.5 % of the cases[28].

However, certain drawbacks of EUS-guided FNA need to be emphasized. In certain cases the procedure is difficult to perform, because of vessel interposition, duodenal stenosis and/or tumor hardness, particularly in chronic pancreatitis, which hampers the overall accuracy of the procedure. In other occasions EUS-guided FNA samples cannot be interpreted due to bleeding or non-cellular samples. A systematic review of 53 studies estimated a negative predictive value of EUS-guided FNA in the diagnosis of pancreatic adenocarcinoma of 60%–70%[15]. In patients with indeterminate or negative findings at the first EUS-guided FNA, presenting a high suspicion of malignancy, repeating the procedure is highly recommended. Several studies have demonstrated that performing a second EUS-guided FNA was very useful for determine the correct and true situation in a high percentage of cases with inconclusive findings at initial EUS-guided FNA; in fact by repeating EUS-guided FNA up to three times sensitivity can increase up to 90%[29-31]. Hence, a new puncture seems necessary to exclude malignancy in cases where the first EUS-guided FNA was negative for malignancy. Even more, when combining all information available on the high accuracy in the evaluation of pancreatic tumors, Eloubeidi *et al*[32] recommend performing an EUS-guided FNA in all patients with solid pancreatic masses.

**ROLE OF RAPID ON-SITE EVALUATION AFTER EUS-GUIDED FNA**

The idea of including rapid on-site evaluation (ROSE) is based on the fact that up to 30% of FNA interpretation may be “non-diagnostic”, because of multiple factors, including scant cellularity and/or “crush artifact” from poor slide preparation. In this setting, ROSE of FNA specimens may be beneficial for rapid clinical diagnosis, probably decreasing the number of non-diagnostic procedures. However, data on the role of ROSE is really limited, with scant data available over the past years. Interestingly, in the recently published guidelines from the European Society of Gastrointestinal Endoscopy, the role of ROSE and its relevance in EUS-guided sampling in gastroenterology has been described [33]. We will try to analyze different aspects of ROSE evaluation after EUS-guided FNA, and its clinical usefulness in the diagnosis of solid pancreatic masses.

***Visual inspection of the sample obtained***

It is not clear whether the evaluation of the sample obtained after the puncture is useful in order to increase the accuracy if EUS-guided FNA. Neither trained technologists nor cytotechnologists, in a prospective double-blinded study, could properly establish the obtention of an adequate sample by gross visual inspection. The kappa score for the agreement between visual evaluation and final microscopic assessment was only of 0.2, which can be considered poor. False-positive assessments occurred in 30% of the slides[34].

***Rapid on-site evaluation performed by cytopathologists and cytotechnicians***

The role of ROSE has been mainly studied in percutaneous FNA. In this setting, ROSE is accepted to be useful, by diminishing the number of inadequate diagnoses. In addition, ROSE may have an impact in costs by decreasing the number of repeat procedures[35-37]. However, data on ROSE in EUS-guided FNA are scarce. Published data suggest that the presence of a cytopathologist during EUS-FNA is cost-effective and useful. We will summarize the most important and relevant data reported in the literature.

Chang *et al*[38] reported a 100% rate of adequate specimen with the on-site evaluation of a cytopathologist during EUS-guided FNA. However, the absence of an on-site cytological evaluation resulted in 29% of patients requiring a second procedure to obtain an adequate specimen. Erickson *et al*[39] also published a lower diagnostic accuracy of EUS-FNA (decreasing between 10% to 15%) without the presence of an on-site cytopathologist. The only concerns were the prolonged procedure time and the potentially increased risk of complications from the need of multiple needle passes. Klapman *et al*[40] demonstrated that an on-site cytopathologist evaluating the samples improved the diagnostic accuracy of EUS-FNA. In their study, they analyzed the EUS-guided FNA results from 2 university hospitals. At Center I, 108 patients underwent EUS-guided FNA in the presence of an on-site cytopathologist. At Center II, 87 patients underwent EUS-guided FNA in the absence of cytopathologist. All procedures at both hospitals were performed by the same endosonographer. At Center I, a definite diagnosis of positive or negative for malignancy was reported in 78% compared with 52% for Center II (OR = 2.94; *P =* 0.001); the rate of patients with an unsatisfactory sample was 9% compared with 20% in Center II (OR = 0.36; *P =* 0.035). Iglesias-Garcia *et al*[14] published their experience in a study including a total of 182 patients. On-site cytopathologist was available in 95 cases (52.2%). A significant higher number of needle passes were performed when ROSE was not available (3.5 ± 1.0 *vs* 2.0 ± 0.7; *P <* 0.001). Presence of on-site cytopathologist was associated with a significantly lower number of inadequate samples (1.0% *vs* 12.6%, *P =* 0.002), and a significantly higher diagnostic sensitivity (96.2% *vs* 78.2%; *P =* 0.002) and overall accuracy (96.8% *vs* 86.2%; *P =* 0.013) for malignancy. In a prospective study evaluating 540 patients who underwent EUS-guided FNA procedures of 656 lesions (mostly of pancreatic masses and lymph nodes), in which ROSE was available in 607 lesions. From all lesions evaluate on-site by a cytologist, 5 of the 243 considered initially benign (2.1%) finally turned to be malignant. In the other hand, from the 300 lesions considered malignant after ROSE, 294 (98%) were at the end malignant on the final report. Agreement was excellent between ROSE and final cytological evaluation (kappa = 84.0%, 95%CI: 80.2-87.7). Compared with the true final status, accuracy for final interpretation was slightly higher for ROSE (95.8%*vs* 93.9%). Most of the discrepancies were related the characteristics of the lesions, either because of the presence of scanty cells, strange morphology, or because of the need of different types of immunostaining needed for final diagnosis[41]. Collins *et al*[42], over a consecutive 3-year period, analyzed 379 patients that underwent ROSE and 377 patients that did not. The percentage of repeat procedures on the non-ROSE group was 5.8%, slightly higher that in the ROSE group (2.9%). The use of the ROSE decreased the number of repeated procedures by approximately 50% (*P =*  0.024). In fact, in patients requiring an additional procedure, the use of ROSE provided a higher number of definitive diagnosis. However, the presence of a cytopathologist is not always possible in many centers, mainly because of the availability according to the organization of the Pathology Department, which is directly associated with costs. Trying to overcome this common situation, Alsohaibani *et al*[43], in a retrospective study suggested that on-site cytotechnologist interpretation of adequacy of tissue samples might also be useful for improving the diagnostic yield of EUS-guided FNA. The patients were divided into 2 groups. In group I, samples were prepared by an endoscopy nurse (*n =* 47) and in-group II by an on-site cytotechnologist (*n =* 55). Pancreatic masses were the main target site. The final diagnosis was higher in the group of on-site cytotechnologists preparing the slides (77% *vs* 53%); suggesting that if an on-site cytopathologist cannot be provided, a trained cytopathology technician should be present to provide an assessment of sample adequacy.

However, not in all studies ROSE was found to be better than the standard approach. In a prospective multicenter study, including 409 patients, two centers used ROSE and two did not[8]. Results were similar in both groups, just differing in a higher negative predictive value in the subgroup of patients with extra-intestinal mass lesions in the group with ROSE. In another study (analyzing 247 pancreatic solid lesions and 276 lymph nodes), a retrospective analysis of risk factors for inadequate EUS-guided FNA specimens was performed. Cytopathological adequacy was higher for lymph nodes (96% *vs* 84%, *P =* 0.008) but not for pancreatic solid lesions (99% *vs* 100%; *P =* 1) if ROSE was available[44].

Finally, a recent meta-analysis aimed to determine whether ROSE, together with the variability of the reference standard ad other sources of heterogeneity may affect the diagnostic yield of EUS-guided FNA when evaluating solid pancreatic masses[45]. Hebert-Magee *et al*[45] included 34 studies. The pooled sensitivity and specificity was 88.6% (95%CI: 87.2-89.9) and 99.3% (95%CI: 98.7-99.7), respectively. The LR+ and LR- were 33.46 (95%CI: 20.76-53.91) and 0.11 (95%CI: 0.08-0.16), respectively. In this study, the main factor determining the accuracy of EUS-guided FNA was the presence of ROSE (*P =* 0.001). Thus, EUS-guided FNA was considered as an effective modality in the diagnosis of pancreatic cancer when evaluating solid pancreatic lesions, higher with the availability of ROSE.

Another important point is the potential application of ROSE with the use on the new histological needles. A very recent study from Krishnan *et al*[46] aimed to investigate the utility of ROSE in achieving a final diagnosis for EUS-guided FNB core specimens. Authors evaluated 60 consecutive patients referred for EUS- guided FNA of lesions inside or adjacent to the gastrointestinal tract. All patients underwent EUS-guided FNB to evaluate the additive value of ROSE to the diagnostic accuracy of specimens obtained using a core biopsy needle. EUS-guided FNB was feasible in all 60 cases. On-site specimen adequacy and final diagnostic accuracy was 58% (95%CI: 45.1-71.2) and 83% (95%CI: 71.9-91.5), respectively. Results were better than those obtained for standard EUS-guided FNA.

Table 1 summarizes the diagnostic accuracy from the most relevant papers comparing EUS-guided FNA or FNB with and without ROSE.

However, little is known on the impact of ROSE on EUS-guided FNA procedural time and it remains unclear whether using ROSE prolongs the procedure or makes it less time-consuming by reducing the number of needle passes. According to some data published, it is assumed that an average time for obtaining the specimen and performing on-site examination is 15 min per sample[47]. Average time used by the cytopathologist for ROSE in computed tomography (CT)-guided and ultrasound-guided FNA specimens is relatively high (48.7 and 44.4 min, respectively)[48].

Regarding complications, scarce information is available from the different studies. In the study from Iglesias-Garcia *et al*[14], complication rate in the group of cases without ROSE was significantly higher, probably related to the higher number of passes needed for obtaining the final diagnosis. However, all complications reported were considered as mild, and no mortality was associated with the procedures.

***Rapid on-site evaluation performed by an endosonographer***

As previously commented, the presence of cytopathologist is not possible in all centers, for all EUS-guided FNA or FNB procedures. In this context, there is a trend to train endosonographers for ROSE during EUS-guided FNA, in order to reduce costs. Some studies have attempted to solve this question.

A prospective double-blind study showed that even experienced endosonographers, trained in the management of samples obtained by FNA, were less accurate than a cytotechnician in assessing specimen adequacy (68%–76% *vs* 82%; *P =* 0.004) and in the determination of malignancy (69%–72% *vs* 89%; *P <* 0.001) [49]. A second study, including 73 procedures, could not find differences when analyzing sample adequacy, number of needle passes or EUS-guided FNA performance characteristics in two different 2-year periods, in one of them ROSE was performed by endosonographers and in the other, this evaluation was performed by cytopathologists[50]. Hayashi *et al*[51] retrospectively evaluated patients from two different periods who underwent EUS-guided FNA for the study of solid pancreatic masses. Before initiating ROSE at the start of second period, two endosonographers underwent training for cytological interpretation, focused on four cytological features of pancreatic ductal carcinoma: anisonucleosis, nuclear membrane irregularity, overlapping, and enlargement. During EUS-guided FNA in period 2, endosonographers classified the Diff-Quik smears under three atypical grades and evaluated the adequacy. One made all diagnoses. The rate of "inconclusive" diagnoses, interpreted as "suspicious," "atypical," and "inadequate for diagnosis" was reduced from 26.4% to 8.2% (*P =* 0.004). Moreover, diagnostic accuracy increased from 69.2% to 91.8% (*P <* 0.001). Authors concluded that samples evaluated by trained endosonographers, with a simple cytological grading system, could be considered very useful in this context.

**CONCLUSION**

EUS-guided FNA and/or FNB are effective modalities for the diagnosis of solid pancreatic masses, with a very high diagnostic accuracy. It is well known that diagnostic performance is clearly associated to the presence of a skilled team, including both endosonographers and cytopathologists. In this context, ROSE appears as a very useful tool for optimizing the yield of this procedure. Although gross visual inspection cannot assess the adequacy of EUS-guided FNA or FNB specimens for cytopathological examination, ROSE performed by cytopathologist provides a highly accurate diagnosis with an excellent agreement with the final cytopathological diagnosis. ROSE may increase adequacy rates of EUS-guided FNA or FNB specimens by 10%-30%. However, we should point out that many recent studies have reported adequacy rates over 90% without the use of ROSE, indicating that, maybe, at high volume centers ROSE may not be indispensable to achieve excellent results. Finally, data on cost**-**effectiveness are very limited. After analyzing all data available, implementation of ROSE should be considered, mainly for learning curve of the technique and at centers in which specimen adequacy rates are below 90%.

**REFERENCES**

1 **Iglesias-García J**, Lindkvist B, Lariño-Noia J, Domínguez-Muñoz JE. The role of EUS in relation to other imaging modalities in the differential diagnosis between mass forming chronic pancreatitis, autoimmune pancreatitis and ductal pancreatic adenocarcinoma. *Rev Esp Enferm Dig* 2012; **104**: 315-321 [PMID: 22738702 DOI: 10.4321/S1130-01082012000600006]

2 **Iglesias García J**, Lariño Noia J, Domínguez Muñoz JE. Endoscopic ultrasound in the diagnosis and staging of pancreatic cancer. *Rev Esp Enferm Dig* 2009; **101**: 631-638 [PMID: 19803666 DOI: 10.4321/S1130-01082009000900006]

3 **Iglesias García J**, Domínguez-Muñoz JE. [Endoscopic ultrasound-guided biopsy for the evaluation of pancreatic tumors]. *Gastroenterol Hepatol* 2007; **30**: 597-601 [PMID: 18028856]

4 **Giovannini M**, Seitz JF, Monges G, Perrier H, Rabbia I. Fine-needle aspiration cytology guided by endoscopic ultrasonography: results in 141 patients. *Endoscopy* 1995; **27**: 171-177 [PMID: 7601050 DOI: 10.1055/s-2007-1005657]

5 **Bhutani MS**, Hawes RH, Baron PL, Sanders-Cliette A, van Velse A, Osborne JF, Hoffman BJ. Endoscopic ultrasound guided fine needle aspiration of malignant pancreatic lesions. *Endoscopy* 1997; **29**: 854-858 [PMID: 9476770 DOI: 10.1055/s-2007-1004321]

6 **Gress FG**, Hawes RH, Savides TJ, Ikenberry SO, Lehman GA. Endoscopic ultrasound-guided fine-needle aspiration biopsy using linear array and radial scanning endosonography. *Gastrointest Endosc* 1997; **45**: 243-250 [PMID: 9087830 DOI: 10.1016/S0016-5107(97)70266-9]

7 **Chang KJ**, Nguyen P, Erickson RA, Durbin TE, Katz KD. The clinical utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic carcinoma. *Gastrointest Endosc* 1997; **45**: 387-393 [PMID: 9165320 DOI: 10.1016/S0016-5107(97)70149-4]

8 **Wiersema MJ**, Vilmann P, Giovannini M, Chang KJ, Wiersema LM. Endosonography-guided fine-needle aspiration biopsy: diagnostic accuracy and complication assessment. *Gastroenterology* 1997; **112**: 1087-1095 [PMID: 9097990 DOI: 10.1016/S0016-5085(97)70164-1]

9 **Gress F**, Gottlieb K, Sherman S, Lehman G. Endoscopic ultrasonography-guided fine-needle aspiration biopsy of suspected pancreatic cancer. *Ann Intern Med* 2001; **134**: 459-464 [PMID: 11255521 DOI: 10.7326/0003-4819-134-6-200103200-00010]

10 **Harewood GC**, Wiersema MJ. Endosonography-guided fine needle aspiration biopsy in the evaluation of pancreatic masses. *Am J Gastroenterol* 2002; **97**: 1386-1391 [PMID: 12094855 DOI: 10.1111/j.1572-0241.2002.05777.x]

11 **Eloubeidi MA**, Chen VK, Eltoum IA, Jhala D, Chhieng DC, Jhala N, Vickers SM, Wilcox CM. Endoscopic ultrasound-guided fine needle aspiration biopsy of patients with suspected pancreatic cancer: diagnostic accuracy and acute and 30-day complications. *Am J Gastroenterol* 2003; **98**: 2663-2668 [PMID: 14687813]

12 **Ardengh JC**, Lopes CV, de Lima LF, de Oliveira JR, Venco F, Santo GC, Modena JL. Diagnosis of pancreatic tumors by endoscopic ultrasound-guided fine-needle aspiration. *World J Gastroenterol* 2007; **13**: 3112-3116 [PMID: 17589929]

13 **Iglesias-Garcia J**, Dominguez-Munoz E, Lozano-Leon A, Abdulkader I, Larino-Noia J, Antunez J, Forteza J. Impact of endoscopic ultrasound-guided fine needle biopsy for diagnosis of pancreatic masses. *World J Gastroenterol* 2007; **13**: 289-293 [PMID: 17226911]

14 **Iglesias-Garcia J**, Dominguez-Munoz JE, Abdulkader I, Larino-Noia J, Eugenyeva E, Lozano-Leon A, Forteza-Vila J. Influence of on-site cytopathology evaluation on the diagnostic accuracy of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) of solid pancreatic masses. *Am J Gastroenterol* 2011; **106**: 1705-1710 [PMID: 21483464 DOI: 10.1038/ajg.2011.119]

15 **Hartwig W**, Schneider L, Diener MK, Bergmann F, Büchler MW, Werner J. Preoperative tissue diagnosis for tumours of the pancreas. *Br J Surg* 2009; **96**: 5-20 [PMID: 19016272 DOI: 10.1002/bjs.6407]

16 **Hewitt MJ**, McPhail MJ, Possamai L, Dhar A, Vlavianos P, Monahan KJ. EUS-guided FNA for diagnosis of solid pancreatic neoplasms: a meta-analysis. *Gastrointest Endosc* 2012; **75**: 319-331 [PMID: 22248600 DOI: 10.1016/j.gie.2011.08.049]

17 **Varadarajulu S**, Tamhane A, Eloubeidi MA. Yield of EUS-guided FNA of pancreatic masses in the presence or the absence of chronic pancreatitis. *Gastrointest Endosc* 2005; **62**: 728-36; quiz 751, 753 [PMID: 16246688]

18 **Ardengh JC**, Lopes CV, Campos AD, Pereira de Lima LF, Venco F, Módena JL. Endoscopic ultrasound and fine needle aspiration in chronic pancreatitis: differential diagnosis between pseudotumoral masses and pancreatic cancer. *JOP* 2007; **8**: 413-421 [PMID: 17625292]

19 **Wiersema MJ**, Levy MJ, Harewood GC, Vazquez-Sequeiros E, Jondal ML, Wiersema LM. Initial experience with EUS-guided trucut needle biopsies of perigastric organs. *Gastrointest Endosc* 2002; **56**: 275-278 [PMID: 12145612 DOI: 10.1016/S0016-5107(02)70193-4]

20 **Levy MJ**, Jondal ML, Clain J, Wiersema MJ. Preliminary experience with an EUS-guided trucut biopsy needle compared with EUS-guided FNA. *Gastrointest Endosc* 2003; **57**: 101-106 [PMID: 12518144 DOI: 10.1067/mge.2003.49]

21 **Levy MJ**, Wiersema MJ. EUS-guided Trucut biopsy. *Gastrointest Endosc* 2005; **62**: 417-426 [PMID: 16111962 DOI: 10.1016/j.gie.2005.04.044]

22 **Jenssen C**, Dietrich CF. Endoscopic ultrasound-guided fine-needle aspiration biopsy and trucut biopsy in gastroenterology - An overview. *Best Pract Res Clin Gastroenterol* 2009; **23**: 743-759 [PMID: 19744637 DOI: 10.1016/j.bpg.2009.05.006]

23 **Larghi A**, Verna EC, Stavropoulos SN, Rotterdam H, Lightdale CJ, Stevens PD. EUS-guided trucut needle biopsies in patients with solid pancreatic masses: a prospective study. *Gastrointest Endosc* 2004; **59**: 185-190 [PMID: 14745390 DOI: 10.1016/S0016-5107(03)02538-0]

24 **Wahnschaffe U**, Ullrich R, Mayerle J, Lerch MM, Zeitz M, Faiss S. EUS-guided Trucut needle biopsies as first-line diagnostic method for patients with intestinal or extraintestinal mass lesions. *Surg Endosc* 2009; **23**: 2351-2355 [PMID: 19263153 DOI: 10.1007/s00464-009-0345-2]

25 **Thomas T**, Kaye PV, Ragunath K, Aithal G. Efficacy, safety, and predictive factors for a positive yield of EUS-guided Trucut biopsy: a large tertiary referral center experience. *Am J Gastroenterol* 2009; **104**: 584-591 [PMID: 19262518 DOI: 10.1038/ajg.2008.97]

26 **Iglesias-Garcia J**, Poley JW, Larghi A, Giovannini M, Petrone MC, Abdulkader I, Monges G, Costamagna G, Arcidiacono P, Biermann K, Rindi G, Bories E, Dogloni C, Bruno M, Dominguez-Muñoz JE. Feasibility and yield of a new EUS histology needle: results from a multicenter, pooled, cohort study. *Gastrointest Endosc* 2011; **73**: 1189-1196 [PMID: 21420083 DOI: 10.1016/j.gie.2011.01.053]

27 **Petrone MC**, Poley JW, Bonzini M, Testoni PA, Abdulkader I, Biermann K, Monges G, Rindi G, Doglioni C, Bruno MJ, Giovannini M, Iglesias-Garcia J, Larghi A, Arcidiacono PG. Interobserver agreement among pathologists regarding core tissue specimens obtained with a new endoscopic ultrasound histology needle; a prospective multicentre study in 50 cases. *Histopathology* 2013; **62**: 602-608 [PMID: 23379782 DOI: 10.1111/his.12041]

28 **Larghi A**, Iglesias-Garcia J, Poley JW, Monges G, Petrone MC, Rindi G, Abdulkader I, Arcidiacono PG, Costamagna G, Biermann K, Bories E, Doglioni C, Dominguez-Muñoz JE, Hassan C, Bruno M, Giovannini M. Feasibility and yield of a novel 22-gauge histology EUS needle in patients with pancreatic masses: a multicenter prospective cohort study. *Surg Endosc* 2013; **27**: 3733-3738 [PMID: 23644834 DOI: 10.1007/s00464-013-2957-9]

29 **Eloubeidi MA**, Varadarajulu S, Desai S, Wilcox CM. Value of repeat endoscopic ultrasound-guided fine needle aspiration for suspected pancreatic cancer. *J Gastroenterol Hepatol* 2008; **23**: 567-570 [PMID: 18397485 DOI: 10.1111/j.1440-1746.2007.05119.x]

30 **Suzuki R**, Lee JH, Krishna SG, Ramireddy S, Qiao W, Weston B, Ross WA, Bhutani MS. Repeat endoscopic ultrasound-guided fine needle aspiration for solid pancreatic lesions at a tertiary referral center will alter the initial inconclusive result. *J Gastrointestin Liver Dis* 2013; **22**: 183-187 [PMID: 23799217]

31 **DeWitt J**, McGreevy K, Sherman S, LeBlanc J. Utility of a repeated EUS at a tertiary-referral center. *Gastrointest Endosc* 2008; **67**: 610-619 [PMID: 18279866 DOI: 10.1016/j.gie.2007.09.037]

32 **Eloubeidi MA**, Tamhane A. Prospective assessment of diagnostic utility and complications of endoscopic ultrasound-guided fine needle aspiration. Results from a newly developed academic endoscopic ultrasound program. *Dig Dis* 2008; **26**: 356-363 [PMID: 19188728 DOI: 10.1159/000177022]

33 **Polkowski M**, Larghi A, Weynand B, Boustière C, Giovannini M, Pujol B, Dumonceau JM. Learning, techniques, and complications of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Technical Guideline. *Endoscopy* 2012; **44**: 190-206 [PMID: 22180307 DOI: 10.1055/s-0031-1291543]

34 **Nguyen YP**, Maple JT, Zhang Q, Ylagan LR, Zhai J, Kohlmeier C, Jonnalagadda S, Early DS, Edmundowicz SA, Azar RR. Reliability of gross visual assessment of specimen adequacy during EUS-guided FNA of pancreatic masses. *Gastrointest Endosc* 2009; **69**: 1264-1270 [PMID: 19243768 DOI: 10.1016/j.gie.2008.08.030]

35 **Kocjan G**, Chandra A, Cross P, Denton K, Giles T, Herbert A, Smith P, Remedios D, Wilson P. BSCC Code of Practice--fine needle aspiration cytology. *Cytopathology* 2009; **20**: 283-296 [PMID: 19754835]

36 **Nasuti JF**, Gupta PK, Baloch ZW. Diagnostic value and cost-effectiveness of on-site evaluation of fine-needle aspiration specimens: review of 5,688 cases. *Diagn Cytopathol* 2002; **27**: 1-4 [PMID: 12112806 DOI: 10.1002/dc.10065]

37 **Woon C**, Bardales RH, Stanley MW, Stelow EB. Rapid assessment of fine needle aspiration and the final diagnosis--how often and why the diagnoses are changed. *Cytojournal* 2006; **3**: 25 [PMID: 17087831 DOI: 10.1186/1742-6413-3-25]

38 **Chang KJ**, Katz KD, Durbin TE, Erickson RA, Butler JA, Lin F, Wuerker RB. Endoscopic ultrasound-guided fine-needle aspiration. *Gastrointest Endosc* 1994; **40**: 694-699 [PMID: 7859967]

39 **Erickson RA**, Sayage-Rabie L, Beissner RS. Factors predicting the number of EUS-guided fine-needle passes for diagnosis of pancreatic malignancies. *Gastrointest Endosc* 2000; **51**: 184-190 [PMID: 10650262 DOI: 10.1016/S0016-5107(00)70416-0]

40 **Klapman JB**, Logrono R, Dye CE, Waxman I. Clinical impact of on-site cytopathology interpretation on endoscopic ultrasound-guided fine needle aspiration. *Am J Gastroenterol* 2003; **98**: 1289-1294 [PMID: 12818271 DOI: 10.1111/j.1572-0241.2003.07472.x]

41 **Eloubeidi MA**, Tamhane A, Jhala N, Chhieng D, Jhala D, Crowe DR, Eltoum IA. Agreement between rapid onsite and final cytologic interpretations of EUS-guided FNA specimens: implications for the endosonographer and patient management. *Am J Gastroenterol* 2006; **101**: 2841-2847 [PMID: 17026562 DOI: 10.1111/j.1572-0241.2006.00852.x]

42 **Collins BT**, Murad FM, Wang JF, Bernadt CT. Rapid on-site evaluation for endoscopic ultrasound-guided fine-needle biopsy of the pancreas decreases the incidence of repeat biopsy procedures. *Cancer Cytopathol* 2013; **121**: 518-524 [PMID: 23983161]

43 **Alsohaibani F**, Girgis S, Sandha GS. Does onsite cytotechnology evaluation improve the accuracy of endoscopic ultrasound-guided fine-needle aspiration biopsy? *Can J Gastroenterol* 2009; **23**: 26-30 [PMID: 19172205]

44 **Cleveland P**, Gill KR, Coe SG, Woodward TA, Raimondo M, Jamil L, Gross SA, Heckman MG, Crook JE, Wallace MB. An evaluation of risk factors for inadequate cytology in EUS-guided FNA of pancreatic tumors and lymph nodes. *Gastrointest Endosc* 2010; **71**: 1194-1199 [PMID: 20598246 DOI: 10.1016/j.gie.2010.01.029]

45 **Hébert-Magee S**, Bae S, Varadarajulu S, Ramesh J, Frost AR, Eloubeidi MA, Eltoum IA. The presence of a cytopathologist increases the diagnostic accuracy of endoscopic ultrasound-guided fine needle aspiration cytology for pancreatic adenocarcinoma: a meta-analysis. *Cytopathology* 2013; **24**: 159-171 [PMID: 23711182 DOI: 10.1111/cyt.12071]

46 **Krishnan K**, Dalal S, Nayar R, Keswani RN, Keefer L, Komanduri S. Rapid on-site evaluation of endoscopic ultrasound core biopsy specimens has excellent specificity and positive predictive value for gastrointestinal lesions. *Dig Dis Sci* 2013; **58**: 2007-2012 [PMID: 23504350 DOI: 10.1007/s10620-013-2613-1]

47 **Pellisé Urquiza M**, Fernández-Esparrach G, Solé M, Colomo L, Castells A, Llach J, Mata A, Bordas JM, Piqué JM, Ginès A. Endoscopic ultrasound-guided fine needle aspiration: predictive factors of accurate diagnosis and cost-minimization analysis of on-site pathologist. *Gastroenterol Hepatol* 2007; **30**: 319-324 [PMID: 17662213 DOI: 10.1157/13107565]

48 **Layfield LJ**, Bentz JS, Gopez EV. Immediate on-site interpretation of fine-needle aspiration smears: a cost and compensation analysis. *Cancer* 2001; **93**: 319-322 [PMID: 11668466]

49 **Savoy AD**, Raimondo M, Woodward TA, Noh K, Pungpapong S, Jones AD, Crook J, Wallace MB. Can endosonographers evaluate on-site cytologic adequacy? A comparison with cytotechnologists. *Gastrointest Endosc* 2007; **65**: 953-957 [PMID: 17531627 DOI: 10.1016/j.gie.2006.11.014]

50 **Hikichi T**, Irisawa A, Bhutani MS, Takagi T, Shibukawa G, Yamamoto G, Wakatsuki T, Imamura H, Takahashi Y, Sato A, Sato M, Ikeda T, Hashimoto Y, Tasaki K, Watanabe K, Ohira H, Obara K. Endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic masses with rapid on-site cytological evaluation by endosonographers without attendance of cytopathologists. *J Gastroenterol* 2009; **44**: 322-328 [PMID: 19274426 DOI: 10.1007/s00535-009-0001-6]

51 **Hayashi T**, Ishiwatari H, Yoshida M, Ono M, Sato T, Miyanishi K, Sato Y, Kobune M, Takimoto R, Mitsuhashi T, Asanuma H, Ogino J, Hasegawa T, Sonoda T, Kato J. Rapid on-site evaluation by endosonographer during endoscopic ultrasound-guided fine needle aspiration for pancreatic solid masses. *J Gastroenterol Hepatol* 2013; **28**: 656-663 [PMID: 23301574 DOI: 10.1111/jgh.12122]

**P-Reviewers:** Hudacko R, Teschke R, Tian YT,Wu H  **S-Editor:** Wen LL  **L-Editor:**  **E-Editor:**

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | **Number of cases** | **Accuracy** |
| **Author** | **Year** | **With ROSE** | **Without ROSE** | **With ROSE** | **Without ROSE** | ***P*** |
| Klapman *et al*[40] | 2003 | 108 | 87 | 78% | 52% | 0.001 |
| Alsohaibani *et al*[43] | 2009 | 47 | 60 | 77% | 53% | 0.001 |
| Iglesias-Garcia *et al*[14] | 2011 | 95 | 987 | 96.8% | 86.2% | 0.013 |
| Collins *et al*[42] | 2013 | 379 | 377 | 97.1% | 94.1% | N.S. |

**Table 1 Diagnostic performance of rapid on-site evaluation by a cytopathologist/cytotechnician in the evaluation of solid pancreatic masses**

ROSE: Rapid on-site evaluation.